Highly schizotypal students have a weaker sense of self-agency

被引:40
作者
Asai, Tomohisa [1 ]
Tanno, Yoshihiko [1 ]
机构
[1] Univ Tokyo, Grad Sch Arts & Sci, Dept Cognit & Behav Sci, Meguro Ku, Tokyo 1538902, Japan
关键词
schizophrenia; schizotypy; sense of self-agency;
D O I
10.1111/j.1440-1819.2007.01768.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Schizotypy can be seen as an indicator of a predisposition to schizophrenia. It is possible that schizotypal people have an abnormal self-consciousness, especially with regard to the sense of self-agency. Students were rated using the Schizotypy Traits Questionnaire (STA). They were asked to press a button, which generated a tone after some delay. They were then required to judge whether they felt they or someone else had generated the tone. The results showed that the high schizotypy group had a weaker sense of self-agency than the low schizotypy group. The present study used an experimental method to show that schizotypal traits are correlated with an abnormal sense of self-agency.
引用
收藏
页码:115 / 119
页数:5
相关论文
共 33 条
  • [31] Experiences of taking neuroleptic medication and impacts on symptoms, sense of self and agency: a systematic review and thematic synthesis of qualitative data
    Thompson, Jemima
    Stansfeld, Jacki L.
    Cooper, Ruth E.
    Morant, Nicola
    Crellin, Nadia E.
    Moncrieff, Joanna
    SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2020, 55 (02) : 151 - 164
  • [32] Assessing the Relationship between Sense of Agency, the Bodily-Self and Stress: Four Virtual-Reality Experiments in Healthy Individuals
    Stern, Yonatan
    Koren, Danny
    Moebus, Renana
    Panishev, Gabriella
    Salomon, Roy
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 20
  • [33] Case series of patients with early psychosis presenting hypoperfusion in angular gyrus and self-disturbance: Implication for the sense of agency and schizophrenia
    Yoshikawa, Akane
    Obata, Youhei
    Kakiuchi, Chihiro
    Nakanishi, Atsushi
    Kimura, Satoshi
    Aoki, Shigeki
    Kato, Tadafumi
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2024, 44 (04) : 706 - 715